Abstract | PURPOSE: METHODS: Eyes with macular edema due to CRVO having occurred not more than 8 weeks previously received either monthly ranibizumab IVI in combination with IH (group I, n = 28) or IH alone (group II, n = 30). From month 2 to 12, the patients in both groups could be treated with monthly intravitreal ranibizumab. The main outcome variables were gain of visual acuity and the course of central retinal thickness as measured with optical coherence tomography. RESULTS: At 12 months, eyes in group I on average gained +28.1 (±19.3) letters compared to +25.2 (±20.9) letters in group II (p = 0.326). This result was achieved with significantly fewer injections in group II. Additionally, 30% of the eyes in group II did not need ranibizumab IVI during the 12 months of the trial. CONCLUSION:
Ranibizumab IVI in addition to IH proved to be highly effective in increasing visual acuity and reducing macular edema secondary to CRVO. Initial IH in early CRVO may be a first treatment option in patients anxious about IVI.
|
Authors | Thomas C Kreutzer, Armin Wolf, Martin Dirisamer, Rupert W Strauss, Paul Foerster, Nicolas Feltgen, Amelie Pielen, Lars-Olof Hattenbach, Anselm Kampik, Siegfried G Priglinger |
Journal | Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde
(Ophthalmologica)
Vol. 233
Issue 1
Pg. 8-17
( 2015)
ISSN: 1423-0267 [Electronic] Switzerland |
PMID | 25502833
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2014 S. Karger AG, Basel. |
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- Ranibizumab
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors
(therapeutic use)
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Blood Viscosity
- Female
- Fluorescein Angiography
- Hemodilution
(methods)
- Humans
- Intravitreal Injections
- Macular Edema
(drug therapy, etiology, therapy)
- Male
- Middle Aged
- Prospective Studies
- Ranibizumab
- Retinal Vein Occlusion
(complications)
- Tomography, Optical Coherence
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Visual Acuity
(physiology)
|